Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International.
| Website | https://www.kyowakirin.com/index.html |
| Revenue | $3 billion |
| Employees | 2,338 (92 on RocketReach) |
| Founded | 1949 |
| Address | 1-9-2 Otemachi Financial City Grand Cube 1-9-2 Otemachi, Otemachi, Tokyo 100-0004, JP |
| Phone | +81 3-5205-7200 |
| Fax | +81 3-5205-7182 |
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
| Web Rank | 63748 |
| Web Visits | 1 Million |
| Keywords | Biotechnology, Drug Discovery, Global Health, Specialty Pharmaceuticals, Pharmaceutical Research, Medicine Development, Clinical Trials, Drug Development, Biologics, Rare Diseases, Innovative Medicines, Healthcare, Therapeutics, Biopharma, Oncology, Immunology, Neurology, Cardiology |
| Competitors | Roche, Pfizer, Novartis, Astellas Pharma US, Eisai Inactive Page, Shionogi Inc., Daiichi Sankyo Co., Ltd., 田辺三菱製薬(株), Santen, Takeda +43 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Kyowa Kirin Co., Ltd. employee's phone or email?
The Kyowa Kirin Co., Ltd. annual revenue was $3 billion in 2026.
Yasuo Fujii is the Director of Kyowa Kirin Co., Ltd..
92 people are employed at Kyowa Kirin Co., Ltd..
Kyowa Kirin Co., Ltd. is based in Otemachi, Tokyo.
The NAICS codes for Kyowa Kirin Co., Ltd. are [325, 32541, 3254, 32].
The SIC codes for Kyowa Kirin Co., Ltd. are [28, 283].